Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Auris Huen, Bradley M. Haverkos, Jasmine M. Zain, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2293-2293
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
Rosalin Mishra, Hima Patel, Samar Alanazi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3464-3464
Open Access | Times Cited: 199
Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy
Belén Toledo, Linrui Zhu Chen, María Paniagua-Sancho, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 50
PI3K–AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds
Yeqin Yuan, Hui‐Zhi Long, Ziwei Zhou, et al.
Biomolecules (2023) Vol. 13, Iss. 1, pp. 93-93
Open Access | Times Cited: 43
Role of protein phosphorylation in cell signaling, disease, and the intervention therapy
Kun Pang, Wei Wang, Jiaxin Qin, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 67
Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
Maria Antonietta Occhiuzzi, Gernando Lico, Giuseppina Ioele, et al.
European Journal of Medicinal Chemistry (2022) Vol. 246, pp. 114971-114971
Closed Access | Times Cited: 43
Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions
Hongyao Li, Xiang Wen, Yueting Ren, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers
Khine Shan, Amalia Bonano-Rios, Nyein Wint Yee Theik, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 1973-1973
Open Access | Times Cited: 11
PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives
Iwona Hus, Bartosz Puła, Tadeusz Robak
Cancers (2022) Vol. 14, Iss. 6, pp. 1571-1571
Open Access | Times Cited: 31
Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study
Jan P. Nicolay, Susanne Melchers, J. Albrecht, et al.
Blood (2023) Vol. 142, Iss. 9, pp. 794-805
Open Access | Times Cited: 21
Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management
Shin Yeu Ong, Jasmine M. Zain
American Journal of Hematology (2024) Vol. 99, Iss. 3, pp. 439-456
Open Access | Times Cited: 8
Novel targeted therapies of T cell lymphomas
Katarzyna Iżykowska, Karolina Rassek, Dorota Korsak, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 49
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Sigrid S. Skånland, Jennifer R. Brown
Haematologica (2022) Vol. 108, Iss. 1, pp. 9-21
Open Access | Times Cited: 28
Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma
Robert Stuver, Alison J. Moskowitz
Cancers (2023) Vol. 15, Iss. 3, pp. 589-589
Open Access | Times Cited: 16
Treatment of extranodal NK/T-cell lymphoma: From past to future
Zheng Yan, Shuna Yao, Zhizhong Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
Xueqin Huang, Li You, Eugenie Nepovimová, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 15
PTCL, NOS: An update on classification, risk-stratification, and treatment
J. Weiss, John Reneau, Ryan A. Wilcox
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 14
Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study
Swaminathan P. Iyer, Auris Huen, Weiyun Z. Ai, et al.
Haematologica (2023)
Open Access | Times Cited: 14
PI3K inhibitors in hematology: When one door closes…
Sigrid S. Skånland, Klaus Okkenhaug, Matthew S. Davids
Clinical Cancer Research (2024) Vol. 30, Iss. 17, pp. 3667-3675
Closed Access | Times Cited: 5
Peripheral T-Cell Lymphomas: Therapeutic Approaches
David Sibon
Cancers (2022) Vol. 14, Iss. 9, pp. 2332-2332
Open Access | Times Cited: 20
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL)
Katherine Case, Pamela B. Allen
Current Hematologic Malignancy Reports (2025) Vol. 20, Iss. 1
Closed Access
Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies
Jonathan D. Greenzaid, Sach Thakker, Ainsley J. Ruley, et al.
Journal of Cutaneous Medicine and Surgery (2025)
Closed Access
Advances in classification and treatment of primary cutaneous lymphomas
Hong Zheng, Lihua Qiu, Chang Liu, et al.
Annals of Hematology (2025)
Open Access
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
Ajay Major, Justin Kline, Theodore Karrison, et al.
Haematologica (2021) Vol. 107, Iss. 7, pp. 1608-1618
Open Access | Times Cited: 25
Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications
Wenli Zhang, Mengmeng Liu, Wei Li, et al.
Chinese Medical Journal (2024) Vol. 137, Iss. 7, pp. 776-790
Open Access | Times Cited: 3
Isoflavone Derivatives as Potential Anticancer Agents: Synthesis and Bioactivity Studies
Mamoalosi A. Selepe
ChemMedChem (2024)
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top